Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy

Introduction: Delandistrogene moxeparvovec (SRP-9001) is an investigational gene transfer therapy designed for targeted expression of SRP-9001 dystrophin protein, a shortened dystrophin retaining key functional domains of the wild-type protein. Methods: This Phase 2, double-blind, two-part (48 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendell, Jerry R., Shieh, Perry B., McDonald, Craig M., Sahenk, Zarife, Lehman, Kelly J., Lowes, Linda P., Reash, Natalie F., Iammarino, Megan A., Alfano, Lindsay N., Sabo, Brenna, Woods, Jeremy D., Skura, Christy L., Mao, Howard C., Staudt, Loretta A., Griffin, Danielle A., Lewis, Sarah, Wang, Shufang, Potter, Rachael A., Singh, Teji, Rodino-Klapac, Louise R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366687/
https://www.ncbi.nlm.nih.gov/pubmed/37497476
http://dx.doi.org/10.3389/fcell.2023.1167762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366687/
https://www.ncbi.nlm.nih.gov/pubmed/37497476
http://dx.doi.org/10.3389/fcell.2023.1167762

Ejemplares similares